Garuda Therapeutics, Inc.

Fundraising by biopharmaceutical companies surged in 2024 to $86.67bn, up 16.2% from $74.59bn in 2023, according to data collected by Biomedtracker. The good fortune was shared across both public and

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Curie.Bio launched on 14 February with $520m to provide $5m-$7m in seed financing per start-up, plus access to in-house expertise and external research services, to help new biopharmas generate enough